Digna Biotech SL, of Madrid, Spain, and the Centro de Investigacion Medica Aplicada de la Universidad de Navarra said the European Union finalized a €3.3 million (US$4.5 million) grant to AIPGENE consortium and, as members of the consortium, Digna and CIMA will receive €500,000 and €800,000, respectively, for the clinical development of a gene therapy product for acute intermittent porphyria. As part of the grant, they will complete a Phase I/II study, with patient enrollment slated to start in early 2012.